Release Date: 30-Aug-2023
Lunsumio is another bispecific antibody in Roche’s cancer drug arsenal, and is used to treat relapsed or refractory follicular lymphoma. It is also the first FDA-approved CD20andtimes;CD3 T-cell engaging bispecific antibody. Because of the significant competition provided by other anticancer medications on the market, Lunsumio sales have been increasingly at a sluggish rate. Lunsumio’s reported sales in the first half of 2023 were CHF 28 Million or US$ 31.92 Million, a significant increase over its sales in the second half of 2022, when Lunsumio worth CHF 14 Million (US$ 16.24 Million) was sold globally. Lunsumio has been the subject of multiple clinical trials in various hematological malignancies, which will allow it to be used in more cancer patients, increasing its uptake and revenues.
Download Global Bispecific Antibody Market Opportunity and Clinical Trials Insight 2023
Download US Bispecific Antibody Market and Clinical Pipeline Insight 2028